Dr Fiona Harris has published in several peer reviewed journals and has presented on numerous occasions at conferences. This included with various masters research articles outline the depth at which she has delved into the study of Geriatric and general patient treatment and care. Dr Fiona Harris has also been involved in several large international multicenter research trials

Research & Presentations

Growth Hormone in the Elderly : An overview.
The Influence of Orthogeriatric Liaison Service on Prognosis Following Fractured Hip: A Retrospective Study.
Osteoporosis in the Elderly.
Screening in the Elderly.
Depression in the Elderly.

Geriatric Unit Meeting, Princess Alexandra Hospital (1994 – current)

Primary Lymphoma of the Thyroid Presenting as Hypercalcaemia.

Presentations at Princess Alexandra Hospital Grand Rounds (1994).

The Influence of Orthogeriatric Liaison Service on Prognosis Following Fractured Hip : A Retrospective Study.
Hip Fracture in the Elderly: Does Growth Hormone/IGF-1 Axis Influence Prognosis?

Australian Society of Geriatric Medicine Conference (1995).

Prognostic Factors in Fractured Neck of femur.

Australian Society of Geriatric Medicine – Queensland Branch Meeting (1995).

Growth Hormone and Osteoporosis.

Princess Alexandra Hospital Week (1995).

General Overview of Pressure Sores.
Difficulties with Swallowing.

Royal Brisbane Hospital (1995).

Prognostic Factors for Fractured Neck of Femur.

Australian Association of Gerontology Conference (1995).

Agitated Behaviour in Nursing Home Residents.
Early Intervention in the Treatment of proximal Femoral Fractures – A Prospective Study.
Interim Care.
Growth Hormone Levels Influence Length of Stay in Elderly Hip Fracture Patients.

Australian Society of Geriatric Meeting Conference (1996).

Publications

A Cost Analysis of Neonatal Intensive and Special Care.

D.I. Tudehope, F. Harris, W. Lee, C. Addison.

Australian Paediatric Journal. 25: 61-65, 1988.

The Clinical Utility of Hygroscopic Heat and Moisture Exchangers in Intensive Care.

R.J. Boots, S. Howe, N. George, F. Harris and J. Faogoali.

Critical Care Medicine – in press.

Abstracts

The Influence of an Orthogeriatric Liaison Service on Prognosis following Fractured Hip: A Retrospective Study.

F.M. Harris, R.J. Boots and D.G. LeCouteur.

Australian and New Zealand Journal of Medicine. 25(5): 597, 1995.

Hip Fracture in the Elderly: Does the Growth Hormone/Insulin Growth Factor-1 Axis Influence Prognosis?

F.M. Harris, R.C. Cuneo and D.G. LeCouteur.

Australian and New Zealand Journal of Medicine. 25(5): 585, 1995.

Agitated Behaviour in Nursing Home Residents.

F.M. Harris, R.C. Cuneo and D.G. LeCouteur.

Australian and New Zealand Journal of Medicine. 1996.

Early Intervention in the Treatment of Proximal Femoral Fractures – A Prospective Study.

F.M. Harris, C.E. Swanson, C.E. Yelland, L. Massey, J. Broome, K. Dimitri, H. Richardson and G. Day.

Australian and New Zealand Journal of Medicine. 1996.

Interim Care.

F.M. Harris, A. Stewart, L. Kratzing, M. Boaden and C.E. Yelland.

Australian and New Zealand Journal of Medicine. 1996.

Growth Hormone Levels Influence Length of Stay in Elderly Hip Fracture Patients.

FM. Harris, R.J. Boots and D.J. LeCouteur.

Australian and New Zealand Journal of Medicine. 1996.

Masters Research

Hip Fracture in the Elderly: Growth Hormone and other Prognostic Factors.

16 Apr 2011 – Role: Investigator Completed GCP training / Qualified through education, training and experience Commencing Jun 2011

Sanofi STUDY

A multinational, multicenter, randomized, double-blind, parallel group, placebo- controlled study of the effect on cognitive performance, safety, and tolerability of
SAR110894D at the doses of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer’s Disease on stable donepezil therapy SAR110894D-DRI10734

Role: Investigator Commenced May 2011

H8A-MC-LZAO

Effect of Passive Immunization on the Progression of Alzheimer’s

Disease: LY2062430 Solanezumab (Phase III)

Role: Investigator Commenced May 2011

CONCERT STUDY

A Phase 3 Multicenter, Open Label Study
Evaluating Dimebon in Patients with Mild-to-Moderate
Alzheimer’s Disease on Donepezil (Protocol No. DIM18 Ext)

Role: Investigator Commenced Aug 2009

H8A-MC-LZAN

Effect of Passive Immunization on the Progression of Alzheimer’s Disease: LY2062430 versus Placebo
(Phase III)

Role: Investigator Commenced Jun 2009

WN22018

A Dose Ranging, Randomized, Double Blind, Parallel- Group Placebo-Controlled Multi-Center Study of RO5313534 Used as Add- On to Donepezil Treatment in Patients with Mild to Moderate Symptoms of Alzheimer’s Disease (Phase II-B)

Role: Investigator Commenced Jul 2009

CONCERT STUDY

A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease on Donepezil (Protocol No. DIM18)

Role: Investigator Commenced Jul 2009

CL2-38093-005

Exploratory study of S 38093 versus placebo in patients with mild to moderate Alzheimer’s Disease. An
international, multi-centre, randomised, double-blind, placebo- controlled phase IIa study.

Role: Investigator Commenced 2008

E2020-GOOO-326

Double–Blind, Parallel –Group Comparison of 23mg Donepezil Sustained Release to 10mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer’s Disease

Role: Investigator Commenced 2008

CENA713DAU01

A 24week , multi-centre, open-label evaluation of compliance and tolerability if the once a day 10cm² Exelon Patch formulation in patients with probable Alzheimer’s Disease.

Role: Investigator Commenced Aug 2007

MEM-MD-71

A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy of Memantine on Functional
Communication in Patients with Alzheimer’s Disease.

Role: Investigator Commenced May 2007

DEB-ZTSR-201

A randomised, double blind, double dummy, oral donepezil controlled study on the safety and efficacy of repeated monthly subcutaneous injections of a sustained release implant of ZT-1 in patients with moderate Alzheimer’s Disease

Role: Investigator Commenced Nov 2006

AVA102670

A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of Rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease (REFLECT-3)

Role: Investigator Commenced Nov 2005

VP-AD-302

A 56 Week, Multicentre, Randomised, Double Blind, Placebo-Controlled study of VP4896 for the treatment of mild-to-moderate Alzheimer’s disease.

Role: Investigator Commenced Oct 2005

VP-AD-302

A 56 Week, Multicentre, Randomised, Double Blind, Placebo-Controlled study of VP4896 for the treatment of mild-to-moderate Alzheimer’s disease.

Role: Investigator Commenced Oct 2005 – Apr 2007

TVP–1012-A001-201

A 52 Week, Multicentre, Randomised, Double Blind, Placebo-Controlled Study of Rasagiline 1mg and 2mg added to Aricept 10mg daily in patients with Mild to Moderate Dementia of the Alzheimer’s Type.

Role: Investigator Commenced Mar 2004

EFC 2724: Xaliproden (SR 57746A):

A randomized, multicenter, double-blind, placebo-controlled, 18-month study of the efficacy of Xaliproden in patients with mild-to-moderate Alzheimer’s disease.

Role: Investigator Commenced 2002

E2020-A001-320

An Open Label Multicentre One Year Extension of the Evaluation of the Safety of Donepezil Hydrochloride in Patients with Dementia associated with Cerebrovascular Disease.

Role: Investigator Commenced 2002

E2020-E044-318

A 52-week, Multicentre Open Label Extension study of the Safety, Tolerability and Efficacy of Donepezil (Aricept®) in Parkinson’s disease (PD) patients with Dementia.

Role: Investigator Commenced 2002